ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

MONOCLONAL ANTIBODY THERAPY ROLE IN AUTOIMMUNE DISEASES

Hussain Ali Alqattan , Abdulrahman Sultan Alluhaybi , Hajar Aown Allah Hamed Alsulami , Leen Hani Natto , Salwa Abdulaziz Alnasheet , Maryam Saud Bu-Arish , Mamdouh Eidhah Alharthi , Safa Mohammedsaeed Nassar , Ebaa Ali Muhammad Alebrahim , Maha Jafar Hersi

Introduction: Monoclonal antibody in the management of autoimmune diseases is considered a new and novel treatment strategy for many types of diseases including but not limited to autoimmune diseases, cancers, and demyelinating diseases. It is characterized by high high efficacy and tolerability. Side effects are notable issue when monoclonal are studied. Many have been shown to cause adverse events. These new medications are expensive, we have seen that most of the well-studied monoclonal antibodies are highly effective in many diseases Aim of work: In this review, we will discuss the most recent evidence regarding the role of antibodies in the management of autoimmune diseases. Methodology: We did a systematic search for the role of antibodies in the management of autoimmune diseases using PubMed search engine (http://www.ncbi.nlm.nih.gov/) and Google Scholar search engine (https://scholar.google.com). Conclusions: Monoclonal antibody in the management of autoimmune diseases is considered a new and novel treatment strategy for many types of diseases including but not limited to autoimmune diseases, cancers, and demyelinating diseases. Side effects are notable issue when monoclonal are studied. These new medications are expensive, we have seen that most of the well-studied monoclonal antibodies are highly effective in many diseases. There are also hybridized or mutated next-generation monoclonal antibodies that have adverse events and higher tolerability. In this review, we discussed the most recent evidence regarding the role of antibodies in the management of autoimmune diseases.

FULL TEXT